ABL Diagnostics
Regulatory News:
ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6)(“Company”) informs its shareholders and all stakeholders that it has been notified of the notice of appeal filed by the Public Prosecutor attached to the Évry-Courcouronnes Judicial Court against the judgment rendered by the Évry-Courcouronnes Commercial Court on October 9, 2026, approving the offer submitted by the Cmpany for the acquisition of IntegraGen’s assets and business activities.
This appeal has suspensive effect. Pending the decision of the Paris Court of Appeal, IntegraGen is therefore placed once again under judicial reorganization proceedings.
ABL Texcell Diagnostics takes note of this situation and remains fully committed throughout the ongoing proceedings.
The Company continues to believe in the industrial, scientific and social merits of its proposed acquisition project and will keep the market informed of any significant developments.
About ABL Texcell Diagnostics (ABLD)
ABL Texcell Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:
- Molecular polymerase chain reaction (PCR) detection – UltraGene, and
- Genotyping by DNA sequencing – DeepChek®.
ABL Texcell Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.
Following the acquisition of TEXCELL’s operations, ABL Texcell Diagnostics is expanding its activities in the life sciences sector by integrating expertise and services dedicated to virology, biosafety testing and biopharmaceutical development support.
ABL Texcell Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.
An expanding portfolio of microbiology products:
- HIV – Drug resistance testing, including a whole genome kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.
- Microbiome and taxonomy – 16s/18s RNA-based analyses.
- Other viral and bacterial targets – Comprehensive molecular assays.
Integrated Solutions
- Real-time syndromic PCR tests
- Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.
ABL Texcell Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.
ABL Texcell Diagnostics SA
Public limited company with a capital of €1,611,465.60
Registered office: 72C route de Thionville - 57140 WOIPPY
552 064 933 R.C.S. METZ
View source version on businesswire.com: https://www.businesswire.com/news/home/20261016244449/en/
ABL Texcell Diagnostics SA
Société anonyme au capital de 1 611 465,60 euros
Headquarters : 72C route de Thionville - 57140 WOIPPY
552 064 933 R.C.S. METZ
Tel : +33 (0)7 83 64 68 50
Email : info@abldiagnostics.com
https://www.abldiagnostics.com/